CCR2 and metabolic disease: Similarly, levels of both CCL2, the main ligand of CCR2, and CCR2, the most potent receptor for myelomonocytic cell recruitment to acutely inflamed sites [151], are increased and correlate with disease progression in PLWH [149,152], characterized by the occurrence of cardiovascular diseases (CVD), HIV-associated neurological disorders (HAND), bone frailty, metabolic disorders, renal and liver failure and cancer [153,154].